Veteran investor and executive with broad experience in corporate finance, strategic partnerships and operational leadership. Denise Reinert brings a market-focused approach to sourcing growth-stage and turnaround opportunities across technology, healthcare and services. She has led capital raises, portfolio governance and operational transformations while working with private equity and venture-backed companies. Background combines senior roles in corporate development and operating teams with an education oriented to finance and management. Typical focus: growth equity, cross-border expansion and board-level oversight.
Veteran investor and executive with broad experience in corporate finance, strategic partnerships and operational leadership. Denise Reinert brings a market-focused approach to sourcing growth-stage and turnaround opportunities across technology, healthcare and services. She has led capital raises, portfolio governance and operational transformations while working with private equity and venture-backed companies. Background combines senior roles in corporate development and operating teams with an education oriented to finance and management. Typical focus: growth equity, cross-border expansion and board-level oversight.
Adopts a market-driven growth equity and turnaround orientation, prioritizing scalable technology, healthcare and services franchises with clear paths to operational improvement. Prefers minority-to-control investments where capital and board guidance accelerate cross‑border expansion, revenue scaling and margin restoration. Underwrites deals with fundamental diligence, conservative leverage and milestone-based capital deployment, emphasizing hands-on portfolio governance, operational playbooks and 3–7 year value-creation horizons to de-risk exits.
Adopts a market-driven growth equity and turnaround orientation, prioritizing scalable technology, healthcare and services franchises with clear paths to operational improvement. Prefers minority-to-control investments where capital and board guidance accelerate cross‑border expansion, revenue scaling and margin restoration. Underwrites deals with fundamental diligence, conservative leverage and milestone-based capital deployment, emphasizing hands-on portfolio governance, operational playbooks and 3–7 year value-creation horizons to de-risk exits.
| Trades 1468 | Longs Won 1024/1468 69% | Profit Factor 23.12 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $555,645.09 |
| Average Win $91,092.7 | Best Trade (Aug 25) $12.91M | Sharpe Ratio -38.5 |
| Average Loss -$9,085.41 | Worst Trade (Sep 01) -$549,525.88 | Z-Score 9.97 (100%) |
| Commissions $0 | Avg. Trade Length 1y 6m 2w 3d | Expectancy $60,793.6 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 50,000 | 45,000 | 40,000 | 35,000 | 30,000 | 25,000 | 20,000 | 15,000 | 10,000 | 5,000 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 16,119 | $3.42M | $4.98M | - | $1.56M | 45.44% | -7.354% |
ABBV AbbVie Inc. | 773 | $124,978.36 | $193,976.62 | - | $68,998.26 | 55.21% | -2.513% |
ABT Abbott Laboratories | 464 | $51,628.2 | $49,044.8 | - | -$2,583.4 | -5% | +0.085% |
ACN Accenture plc Class A | 47 | $15,622.51 | $7,798.24 | - | -$7,824.27 | -50.08% | +1.611% |
ADBE Adobe Inc. | 567 | $277,522.69 | $141,982.47 | - | -$135,540.22 | -48.84% | +1.013% |
ADI Analog Devices, Inc. | 94 | $25,492.8 | $34,536.54 | - | $9,043.74 | 35.48% | +0.202% |
ADNT Adient plc | 9 | $330 | $189.36 | - | -$140.64 | -42.62% | -3.839% |
ADP Automatic Data Processing Inc. | 323 | $79,228.11 | $86,066.58 | - | $6,838.47 | 8.63% | +0.982% |
AEE Ameren Corporation | 95 | $9,916 | $10,412.95 | - | $496.95 | 5.01% | +0.791% |
AEP American Electric Power Company, Inc. | 70 | $9,175.66 | $8,949.5 | - | -$226.16 | -2.46% | +0.055% |
AM Antero Midstream Corporation | 500 | $5,800 | $10,985 | - | $5,185 | 89.4% | +1.949% |
AMAT Applied Materials, Inc. | 192 | $28,901.92 | $97,472.64 | - | $68,570.72 | 237.25% | +1.176% |
AMCR Amcor plc | 432 | $17,172 | $19,388.16 | - | $2,216.16 | 12.91% | -0.598% |
AMGN Amgen Inc. | 175 | $50,157.43 | $67,403 | - | $17,245.57 | 34.38% | -0.64% |
AMLP Alerian MLP ETF | 325 | $12,917.25 | $17,979 | - | $5,061.75 | 39.19% | +0.894% |
AMP Ameriprise Financial, Inc. | 116 | $61,913 | $63,317.44 | - | $1,404.44 | 2.27% | +0.253% |
AMT American Tower Corporation | 32 | $6,323.03 | $5,547.52 | - | -$775.51 | -12.26% | -0.631% |
AMZN Amazon.com Inc | 353 | $49,577.8 | $95,867.74 | - | $46,289.94 | 93.37% | +15.321% |
AOA iShares Core Aggressive Allocation ETF | 131 | $9,042.14 | $12,674.25 | - | $3,632.11 | 40.17% | +0.301% |
APD Air Products and Chemicals, Inc. | 162 | $48,451.38 | $47,772.18 | - | -$679.2 | -1.4% | -1.769% |